The U.S. Food and Drug Administration (FDA) has issued permission for urgent use of Sotrovimab on the basis of monoclonal antibodies for the treatment of Covid-19 in minor or mild severity as the FDA reported.
The drug can be used for the treatment of adults and children 12 years of age and older weighing at least 40 kilograms with positive results of direct testing for SARS-CoV-2 who have a high risk of progression to the severe form of Covid-19, including hospitalization and death. It includes people at the age of 65 and older or people with particular diseases.
The safety and efficiency of this investigative therapy are still being estimated.
Meanwhile, Sotrovimab is not allowed for patients hospitalized due to the coronavirus or if they need oxygen therapy.
Sotrovimab is also known as VIR-7831 and GSK4182136 is a drug on the basis of monoclonal antibodies. It is developed by British GlaxoSmithKline and American Vir Biotechnology.
As we reported, the Indian coronavirus mutation is transmitted 80% faster than the British. According to the scientist, it is the Indian strain that will dominate in the near future.